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Abstract 
Aim: Mesenchymal stem cells (MSC) possess the distinctive feature of homing in on and engrafting 
into the tumor stroma making their therapeutic applications in cancer treatment very promising. 
Research into new effectors and external stimuli, which can selectively trigger the release of 
cytotoxic species from MSC toward the cancer cells, significantly raises their potential.  
Main methods: Shock waves (SW) have recently gained recognition for their ability to induce 
specific biological effects, such as the local generation of cytotoxic reactive oxygen species (ROS) 
in a non-invasive and tunable manner. We thus investigate whether MSC are able to generate ROS 
and, in turn, affect cancer cell growth when in co-colture with human glioblastoma (U87) or 
osteorsarcoma (U2OS) cells and exposed to SW. 
Key findings: MSC were found to be the cell line that was most sensitive to SW treatment as shown 
by SW-induced ROS production and cytotoxicity. Notably, U87 and U2OS cancer cell growth was 
unaffected by SW exposure. However, significant decreases in cancer cell growth, 1.8 fold for U87 
and 2.3 fold for U2OS, were observed 24 h after the SW treatment of MSC co-cultures with cancer 
cells. The ROS production induced in MSC by SW exposure was then responsible for lipid 
peroxidation and cell death in U87 and U2OS cells co-cultured with MSC. 
Significance: This experiment highlights the unique ability of MSC to generate ROS upon SW 
treatment and induce the cell death of co-cultured cancer cells. SW might therefore be proposed as 
an innovative tool for MSC-mediated cancer treatment. 
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1. Introduction 
Cancer remains one of the leading causes of morbidity and mortality throughout the world. 
Several types of cancer do not respond to first line therapies, such as chemotherapy and 
radiotherapy, and one of the major challenges is to find effective anticancer treatments able to 
completely eradicate the tumor, while keeping systemic toxicity at minimum [1]. In recent decades, 
various tumor-targeted therapeutic approaches have been developed at a molecular, cellular and 
tissue level [2]. In the last years, mesenchymal stem cells (MSC) have received much attention not 
only as candidates for regenerative medicine regimens, but also for their potential as “smart” 
delivery systems of chemotherapeutics and nanoparticles [3-8]. MSC are multipotent cells 
characterized by tropism toward primary and metastatic tumor locations [9,4,8]. It has been shown 
that specific tumor-derived growth factors secreted by cancer cells, stimulate MSC tropism, 
including cell-cell and paracrine interactions, thus creating a tight correlation between the two 
cellular populations [10]. This ability to migrate specifically to tumors has meant that MSC have 
been used to deliver anticancer and biological agents to tumor tissues [11,12].  
Cytotoxic agent-loaded nanoparticles (NPs) have been for instance incorporated into MSC 
or anchored on their cell surface [13] making NPs engineered MSC act as “Trojan horses” by 
delivering the therapeutics to the targeted sites. In principle, strategies that exploit MSC as delivery 
vehicles of cytotoxic compounds, without the need for sophisticated cells engineering would be 
highly beneficial. In this regard, several recent studies have focused on the development of new 
anticancer approaches in which the cytotoxicity of conventional drugs or specifically engineered 
nanoparticles and molecules is triggered by external stimuli, such as light and ultrasound [14-16]. 
For instance, the activation of responsive molecules by light results in an energy transfer cascade 
that ultimately leads to the formation of cytotoxic reactive oxygen species (ROS), which are the 
effectors of apoptotic and necrotic cell death [17]. However, the low tissue penetration depth of 
light is a major shortcoming of this technique [17]. Therefore, novel systems capable of penetrating 
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more deeply into tissue and to induce the release of ROS into the tumor stroma are required. In this 
respect, we have recently introduced a novel non-invasive treatment, which induces tumor cell 
death by triggering the cytotoxicity of responsive molecules via shock waves (SW) [18,19].  
SW have been used for many years in extracorporeal shock wave lithotripsy, while more 
recent SW applications include drug delivery and gene therapy [20-22]. SW are pulsed ultrasound 
which are characterized by microsecond pressure surges and sudden positive pressure peak (up to 
values of about 100 MPa), followed by smaller negative pressure peak (about 10 MPa) [22]. SW 
can cause direct physical and indirect biological effects that can be amplified by sensitizer 
molecules [19]. Little is known about the mechanism responsible for the biological effects triggered 
by ultrasound, though the “intra-membrane cavitation model” reported by Krasovitski et al. [23] is 
an important attempt to explain the effect. According to this model, ultrasound with specific 
characteristics can induce modifications in the lipid bilayer of cell membrane leading to 
intracellular deformations. Moreover, under appropriate conditions, a significant oxidative stress 
may occur during SW exposure due to the imbalance between ROS production and antioxidant 
defence [24], resulting in ROS-induced cytotoxicity [25]. However, the in vivo treatment of solid 
tumors by SW alone has been shown to be ineffective [26].  
It is currently believed that only unregulated levels of ROS are harmful for cells, while 
regulated ROS production promotes essential signalling pathways, which control cell functions 
such as cells proliferation, differentiation and apoptosis. MSC osteogenic and adipogenic 
differentiation are regulated by the intracellular levels of ROS [27]. Understanding the impact of 
ROS on MSC may reveal how these cells can be harnessed for therapeutic purposes. Our hypothesis 
is that upon selective exposure to external SW, MSC could generate a significant amount of ROS 
able to kill cancer cells, thus functioning as cell-based “ROS-producers” for targeted tumor 
treatment. By using in vitro MSC co-cultures with human glioblastoma (U87) and osteosarcoma 
(U2OS) cancer cell lines, we demonstrated for the first time that MSC are able to kill cancer cells 
under the exclusive control of SW irradiation.  
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2. Materials and Methods 
2.1. Cell lines and culturing 
 Bone marrow (BM) samples were obtained from patients who underwent surgery at Rizzoli 
Orthopaedic Institute (Bologna, Italy); informed consent was given according to a protocol 
approved by the Local Ethics Committee (Prot.gen. 0004377). Isolation and culture expansion of 
human MSC was performed as previously described [28]. Briefly, nucleated cells were isolated 
using a density gradient solution (Ficoll-Paque PREMIUM, Ge Healthcare, Uppsala, Sweden) and 
plated in culture flasks with α-Modified Minimum Essential Medium (α-MEM, Lonza, Verviers, 
Belgium), which was supplemented with 20% fetal bovine serum (FBS, Lonza) and 1% 
GlutaMAX™ (Invitrogen-Life Technologies, Paisley, UK). The cells were cultured in a humidified 
atmosphere of 5% CO2 air at 37°C and the medium changed every 3-4 days. When adherent cells 
reached approximately 70-80% confluence, they were detached by mild trypsinization (TrypLE 
Select; Gibco Invitrogen Corp., Grand Island, NY, USA) and seeded into new culture flasks at a 
density of 4 × 103 cells/cm2 for continued passages. For the experiments, MSC were used between 
passages 3 and 6, and tumor cells between passages 4 and 25. Human glioblastoma-astrocytoma 
U87MG-RFP cells (U87-RFP) were kindly provided by Dr Laura Falchetti (CNR, Roma, Italy). 
Human osteosarcoma U2OS-TUBA1B were purchased from Sigma Aldrich (St. Louis, MO, USA) 
and the genomic TUBA1B gene was endogenously tagged with a Red Fluorescent Protein (RFP) 
gene using the CompoZr® Zinc Finger Nuclease technology (U2OS-RFP). The human dermal 
fibroblast cell line, HDF 106, was purchased from the European Collection of Authenticated Cell 
Cultures (ECACC, Salisbury, UK). 
 U87-RFP cells were cultured in Minimum Essential Medium Eagle (EMEM, Sigma Aldrich, 
Milano, Italy), U2OS-RFP cells were cultured in McCoy's 5A (Sigma Aldrich) and HDF 106 cells 
were cultured in DMEM (Sigma Aldrich). All media were supplemented with 10% FBS (Lonza), 2 
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mM L-glutamine, 100 UI/mL penicillin and 100 µg/mL streptomycin (Sigma Aldrich). All cell lines 
were maintained in a humidified atmosphere of 5% CO2 air at 37°C. 
 
2.2. Intracellular glutathione determination 
 The intracellular content of glutathione (GSH) of MSC, HDF 106, U87-RFP and U2OS-RFP 
cells was determined using the Glutathione Assay Kit (Sigma Aldrich), according to manufacturer’s 
instructions. The GSH content (nmol GSH) was normalized to µg of protein for each sample by 
quantifying cell protein concentration (µg/mL) using the Quant-iT Protein Assay Kit on the 
fluorometer Qubit (Invitrogen-Life Technologies). 
 
2.3. In vitro SW treatment 
 For SW experiments, single cell lines (MSC, HDF 106, U87-RFP and U2OS-RFP) and co-
cultures (MSC with U2OS-RFP/U87-RFP cells and HDF 106 with U2OS-RFP/U87-RFP cells, at a 
ratio of 1:3) in the exponential growth phase, were washed three times with phosphate buffered 
saline (PBS) and harvested by trypsinization. 4.0 × 105 cells were then seeded in PBS into a 
polystyrene culture dish (Trasadingen, Switzerland) for SW exposure using a piezoelectric device 
(Piezoson 100; Richard Wolf, Knittlingen, Germany) which generated focused SW at an energy 
flux density (i.e. energy at the focal point) of 0.22 mJ/mm2, characterized by a positive pressure 
peak of 31 MPa, for 1000 impulses at a frequency of 4 impulses/s. SW exposure conditions were 
chosen, according to the literature, in order to obtain intramembrane cavitation without direct 
mechanical cell damage [18,29,26,30]. Experiments were carried out in a single SW treatment. 
Specifically, the focal area, defined as the area in which 50% of the maximum energy is achieved, is 
assumed to be an elliptical focus cigar with a length of 10 mm in the direction of the shock wave 
propagation axis and a diameter of 2.5 mm perpendicular to this axis. To control the SW penetration 
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depth we used an acoustically adapted gel pad of 4.0 cm thickness, which allowed a 5 mm SW 
penetration depth. The polystyrene culture dish was placed in close contact with the gel pad secured 
on the transducer using common ultrasound gel.   
The effect of SW treatment on single cell lines (MSC, HDF 106, U87-RFP and U2OS-RFP) and on 
co-cultures (MSC with U2OS-RFP/U87-RFP cells and HDF 106 with U2OS-RFP/U87-RFP) was 
monitored by fluorescence microscopy (DMI4000B Leica, Wetzlar, Germany), and cells were 
manually counted 24, 48 and 72 h after SW treatment. 
 
2.4. Cell growth assay 
Each experiment was carried out by exposing 4.0 x 105 cells to SW and by subsequently 
seeding 2.0 x 104 cells of either single cell line or co-cultured cell sample in 2.0 mL of culture 
medium in replicates in 6-well culture plates. Thanks to the RFP fluorescent protein present in the 
two tumor cell lines, it was possible to discriminate between MSC and tumor cells and to obtain the 
cell count for each cell lines. A total of 5 fields were analysed at a magnification of 10x for each 
treatment condition in three independent experiments at 24, 48 and 72 h after SW treatment.  
Moreover, co-culture cell growth after SW treatment was determined also in the presence of 
a ROS scavenger in order to investigate the influence ROS production has on cell growth after SW 
exposure. Briefly, MSC were exposed to the ROS scavenger N-Acetyl-L-cysteine (NAC, Sigma 
Aldrich), whose primary function is the inhibition of ROS induced cellular damage [31]. MSC were 
pre-incubated with NAC (5 mM) in culture medium without FBS at 37°C for 1 h, washed in PBS 
and co-cultured with either U87-RFP or U2OS-RFP for the SW treatment; cell growth was then 
monitored as previously described. Furthermore, it was decided to investigate whether factors other 
than ROS were responsible for cancer cell growth decrease. Therefore, we collected MSC culture 
media at 0.5, 5 and 20 h after the SW treatment of MSC, with the final aim to incubate directly with 
these media either U87-RFP or U2OS-RFP cells previously plated alone.  
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2.5. Flow cytometric analyses 
 ROS generation, cell death and lipid peroxidation were assessed using flow cytometric 
assays on a C6 flow cytometer (Accurri Cytometers, Milano, Italy). In order to evaluate whether 
SW exposure induces ROS production in different cell lines, 2,7-dichlorofluorescein (DCF) 
diacetate (DA) (DCF-DA; Molecular Probes, Carlsbad, CA, USA) was used as an intracellular 
probe for oxidative stress detection. DCF-DA is a stable, non-fluorescent molecule that readily 
crosses the cell membrane and is hydrolysed, by intracellular esterases, to the non-fluorescent 
DCFH. This is in turn rapidly oxidized in the presence of peroxides to highly fluorescent DCF upon 
oxidation by ROS [32]. Briefly, cells were incubated with 10 µM DCF-DA for 30 min, washed with 
PBS, trypsinized, subjected to SW exposure and analysed at 5, 15, 30 and 60 min. ROS production 
was expressed as integrated median fluorescence intensity (iMFI), which is the product of ROS-
producing cell frequency and the median fluorescence intensity of the cells [33]. ROS production 
by MSC and HDF 106 after SW exposure was investigated also in the NAC (Sigma Aldrich) pre-
treated cells. Briefly, MSC were pre-incubated with NAC (5 mM) in culture medium without FBS 
at 37°C for 1 h. Cells were then PBS washed and incubated with DCF-DA, as previously described. 
 Cell death was evaluated using the Dead Cell Apoptosis Kit with Annexin V-Alexa Fluor® 
and propidium iodide (PI, Life Technologies, Milano, Italy). 4.0 × 105 cells were treated and cell 
death was evaluated 24 h after SW treatment. Briefly, cells were detached with trypsin and washed 
with PBS at 1,500 rpm for 5 min and then re-suspended with 1x Annexin-binding buffer and stained 
with Annexin V-Alexa Fluor® and PI. Sample analyses were carried out at 488 nm excitation to 
measure Annexin V-Alexa Fluor® and at 530 nm to measure PI, respectively. 10,000 events were 
considered in the analyses and any cell debris that displayed low forward light scatter and side light 
scatter was excluded from the analyses. The two different staining types allowed us to identify 
apoptotic (Annexin V-Alexa Fluor® positive) and necrotic cells (Annexin V-Alexa Fluor® and PI 
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positive) and tell them apart from viable cells (Annexin V-Alexa Fluor® and PI negative). All 
analyses were performed using FCS Express software version 4 (BD Bioscience, Milano, Italy).  
 The Image-iT® Lipid Peroxidation Kit (Life Technologies) was used, according to 
manufacturer’s instructions, to investigate whether SW treatment was able to induce damage via the 
oxidative degradation of cellular lipids. The BODIPY 581/591 C11 reagent is a fluorescent lipid 
peroxidation reporter molecule that shifts its fluorescence from red to green when challenged with 
oxidizing agents [34]. Briefly, 4.0 × 105 cells were treated with SW at an energy flux density of 
0.22 mJ/mm2 for 1000 impulses (4 impulses/s). The reagent was added to cells for 30 min 
incubation at 37°C and then lipid peroxidation was evaluated 12 and 24 h after SW treatment. Cells 
were also treated with cumene hydroperoxide (200 mM) for 2 h without SW exposure as a positive 
control. Cells were detached by trypsin, washed with PBS and data were acquired by reading 
fluorescence at two separate wavelengths: one at excitation/emission of 581/591 nm for the reduced 
dye, and the other at excitation/emission of 488/510 nm for the oxidized dye. The ratio between 
emission fluorescence intensities at 590 nm to 510 nm gave us the read-out for lipid peroxidation in 
cells. 
 
2.6. Statistical analyses 
Data are shown as average values ± standard deviation of three independent experiments. 
Statistical analyses were performed on Graph-Pad Prism 6.0 software (La Jolla, CA, USA); two-
way analysis of variance and Bonferroni’s test were used to calculate the threshold of significance. 
The statistical significance threshold was set at p < 0.05. 
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3. Results 
3.1. Intracellular glutathione level 
GSH is an important intracellular low molecular weight tripeptide thiol that plays numerous 
important biological functions, including protecting cells from toxic compounds such as ROS [35]. 
Therefore, we determined the GSH level in all the considered cell lines. No significant differences 
of intracellular GSH levels were observed in MSC, HDF 106 and U87-RFP cells, whereas a 
significantly higher GSH level was observed in U2OS-RFP cells (Fig. 1).  
 
                           
 
Fig. 1. Intracellular GSH content according to cell type. The reduced GSH content of human MSC, 
HDF 106, U87-RFP and U2OS-RFP cells was measured at a basal level, i.e. in untreated cells, and 
was expressed as nmol/µg protein. Statistical significance between MSC and the other cell lines: ** 
p < 0.01. 
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3.2. Effect of SW treatment on cell growth and ROS production in single cell lines 
MSC, HDF 106, U87-RFP and U2OS-RFP cell lines were separately exposed to the same 
SW treatment. As MSC and HDF 106 cells displayed a cell population doubling time that was 
roughly 2 times lower than that of U87-RFP and U20S-RFP cells, cell growth data are expressed as 
a percentage of control cells, i.e. untreated cells at the corresponding time point. A significant 
decrease in cell growth was observed only in MSC from 24 to 72 h (Fig. 2A, 80.31 ± 7.50% at 24 h, 
78.00 ± 8.17% at 48 h and 64.43 ± 14.96% at 72 h) and in HDF 106 at 24 h (Fig. 2B, 79.75 ± 1.77% 
at 24 h), whereas U87-RFP and U2OS-RFP cell growth was unaffected by SW exposure (Fig. 2C, 
D). We then carried out the DCF-DA cytofluorimetric assay in order to quantitatively measure the 
ROS production that was induced by SW exposure in MSC, HDF 106, U87-RFP and U2OS-RFP. 
As compared to untreated MSC, SW-treated MSC showed a statistically significant ROS production 
from 1 up to 60 min after SW treatment (Fig. 3A, p < 0.001). Moreover, the ROS production after 
SW exposure of NAC pre-treated MSC was strongly decreased indicating a specificity of ROS 
production induced by SW treatment (Fig. 3B). A lower but statistically significant ROS production 
was observed also in HDF 106 cells from 15 up to 30 min after SW treatment, as compared to 
untreated HDF 106 cells (Fig. 3C, p < 0.05). Interestingly, no significant increase in ROS 
production was observed in either U87-RFP or U2OS-RFP cells after SW treatment, as compared to 
untreated cancer cells (Fig. 3D-E). Therefore, it is possible to state that MSC are more sensitive to 
SW treatment than the other cell lines, according to the data of intracellular GSH level (Fig. 1), cell 
growth (Fig. 2) and ROS production (Fig. 3).  
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Fig. 2. Effects of SW treatment on the single cell line growth. MSC (A), HDF 106 (B), U87-RFP 
(C) and U2OS-RFP (D) cells were exposed to SW treatment at an energy flux density (EFD) of 
0.22 mJ/mm2 for 1000 impulses (4 impulses/s). Cell growth was evaluated after 24, 48 and 72 h by 
fluorescence microscopy. Statistical significance between untreated cells (full bars) and SW-treated 
cells (dashed bars) at the respective time point: * p < 0.05, ** p < 0.01. 
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Fig. 3. ROS production of single cell lines after SW treatment. MSC (A, B), HDF 106 (C), U87-
RFP (D) and U2OS-RFP (E) cells were exposed to SW treatment at an energy flux density (EFD) of 
0.22 mJ/mm2 for 1000 impulses (4 impulses/s) and ROS production at 1, 5, 15, 30 and 60 min was 
investigated using the DCF-DA assay. The ROS production of MSC cells was also determined by 
incubating cells with the ROS scavenger N-Acetyl-L-cysteine (NAC, 5 mM; panel B) 1 h before 
SW treatment (EFD 0.22 mJ/mm2 for 1000 impulses, 4 impulses/s). Statistical significance between 
untreated cells or co-cultures (full bars) and SW-treated cells or co-cultures (dashed bars): * p < 
0.05, *** p < 0.001. 
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3.3. Effect of SW treatment on cell growth and ROS production of co-cultures 
Fig. 4 reports the effect of a single SW treatment on MSC that were co-cultured with either 
U87-RFP or U2OS-RFP cells. A statistically significant decrease in cell growth was observed in 
both co-cultures (Fig. 4A-B). Specifically, 24 h after SW treatment we observed a cancer cell 
growth decrease of 1.8 fold in the MSC/U87-RFP co-culture (Fig. 4A, 41.32 ± 10.25% at 24 h) and 
of 2.3 fold in the MSC/U2OS-RFP co-culture (Fig. 4B, 32.80 ± 3.78% at 24 h), both results are 
compared to the cancer cell growth of the respective untreated co-cultures (Fig. 4A and B, p < 
0.001). Moreover, a less significant cancer cell growth decrease was observed 48 and 72 h after SW 
treatment in both cancer cell co-cultures (Fig 4A, 54.63 ± 3.40% at 48 h, 58.68 ± 4.35% at 72 h and 
Fig. 4B, 59.95 ± 6.53% at 48 h, 56.23 ± 3.12% at 72 h, respectively) as compared to the cancer cell 
growth of the respective untreated co-cultures (Fig. 4A and B, p < 0.01). 
 Furthermore, it was investigated whether the SW-induced tumor cell number decrease could 
be ascribed to the ROS produced by MSC upon SW treatment. Therefore, we performed the same 
experiments, but with MSC pre-treated with 5 mM NAC before SW treatment. As reported in Fig. 
4C and D, a lower decrease in cancer cell number was detected in the co-cultures with NAC pre-
treated MSC; specifically, we did not observe the same significant reduction in the cell growth in 
U87-RFP cells at 24 h (Fig. 4C, p < 0.01) and in U2OS-RFP cells at 24 h (Fig. 4D, p < 0.05), as 
compared to the respective SW treated co-cultures in which MSC were not exposed to NAC (Fig. 
4A and B). Moreover, no cancer cell number decrease was observed for MSC incubated with NAC 
and co-cultured with either U87-RFP or U2OS-RFP 48 and 72 h after SW treatment (Fig. 4C and 
D).  
The effect of SW treatment on co-cultures of the same cancer cells, i.e. U87-RFP and 
U2OS-RFP, with HDF 106 cells was investigated in order to define whether MSC are 
characteristic/selective in inducing a SW-mediated cell growth decrease of co-cultured cancer cells. 
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SW treatment did not affect cancer cell growth (Fig. 4E-F) when HDF 106 cells were co-cultured 
with either U87-RFP or U2OS-RFP cells.  
Furthermore, MSC alone were exposed to the same SW treatment and their collected culture 
media were incubated with either U87-RFP or U2OS-RFP cells previously cultured alone. This was 
done in order to investigate whether further factors, other than ROS formed upon SW exposure, 
might be responsible for the observed cancer cell growth decrease. Indeed, no change in cancer cell 
growth was observed up to 72 h (data not shown), suggesting that ROS generated in situ by MSC 
under SW exposure, are the only effectors of cancer cell growth decrease. 
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Fig. 4. Effect of SW treatment on the co-culture cell growth. Co-cultures of MSC and either 
U87RFP (A) or U2OS-RFP (B) cells were exposed to SW treatment at an energy flux density 
(EFD) of 0.22 mJ/mm2 for 1000 impulses (4 impulses/s). The same SW treatment was carried out 
also on co-cultures of MSC, previously incubated with the ROS scavenger N-Acetyl-L-cysteine 
(NAC, 5 mM) for 1 h, with either U87-RFP (C) or U2OS-RFP (D) cells. The same SW treatment 
was carried out also on co-cultures of HDF 106 with either U87-RFP (E) or U2OS-RFP (F) cells as 
a co-culture control. Cell growth was evaluated at 24, 48 and 72 h by fluorescence microscopy. 
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Statistical significance between untreated co-cultures (full bars) and SW-treated co-cultures (dashed 
bars) at the respective time point: * p < 0.05, ** p < 0.01, *** p < 0.001 and between co-cultures 
with MSC or with MSC incubated with NAC (+ NAC): # p < 0.05, ## p < 0.01. 
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3.4. Lipid peroxidation on MSC co-cultures after SW treatment 
The analysis of lipid peroxidation was performed in order to investigate whether ROS 
production by MSC under SW exposure was able to induce downstream events in the co-cultures 
that undergo cancer cell growth decrease. As reported in Fig. 5, 12 h after SW treatment, a large 
amount of reduced lipid intermediates were detected in all the considered cell models (high reduced 
590/oxidized 510 ratio). Twenty-four hours after SW exposure, a lower ratio of reduced 
590/oxidized 510 was observed, accounting for the presence of a large amount of oxidized lipid 
intermediates (Fig. 5). In particular, we observed that both MSC alone and in co-culture with 
U2OS-RFP cells became positive to the green channel after SW treatment, indicating the presence 
of oxidized lipid peroxidation intermediates. Specifically, by comparing the reduced 590/oxidized 
510 ratio 12 h and 24 h after SW treatment, a significant formation of oxidized lipid intermediates 
could be detected; in particular a nearly 2.5, 1.8 and 4.4 fold increase was observed for MSC (p < 
0.01), MSC/U87-RFP co-culture (p < 0.01) and MSC/U2OS-RFP co-culture (p < 0.001), 
respectively (Fig. 5).  
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Fig. 5. Lipid peroxidation occurrence after SW treatment. MSC and MSC co-cultured with either 
U87-RFP or U2OS-RFP cells were exposed to SW treatment at an energy flux density (EFD) of 
0.22 mJ/mm2 for 1000 impulses (4 impulses/s). Lipid peroxidation was evaluated 12 and 24 h after 
SW treatment by cytofluorimetric assay. Statistical significance between lipid peroxidation 12 h and 
24 h after SW treatment: ** p < 0.01, *** p < 0.001. 
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3.5. Cell death analysis on MSC co-cultures after SW treatment  
 A cell death analysis by flow cytometric assay was performed 24 h after SW treatment to 
determine whether the cancer cell growth decrease induced by SW treatment of MSC co-culture 
was due to apoptosis and/or necrosis. After SW treatment, no significant increase in apoptotic or 
necrotic cells was observed in both cancer cell lines compared to untreated cells, whereas a 
significant increase in necrotic cells was observed in MSC (Tab.1, p < 0.05), as compared to 
untreated cells. Interestingly, a significant increase in both apoptotic and necrotic cells was 
observed, as compared to untreated co-cultures, in the MSC co-cultures with U87-RFP cells (Tab.1, 
p < 0.01) and U2OS-RFP cells (Tab.1, p < 0.01) after SW treatment. 
 
Tab.1. Cell death detection 24 h after SW treatment. 
 
 Live cells Apoptotic cells Necrotic cells 
MSC 86.84 ± 10.52 7.10 ± 1.13 6.06 ± 8.67 
MSC + SW  75.35 ± 6.01 9.55 ± 3.61 15.10 ± 3.75 * 
U87-RFP  92.23 ± 8.17 2.15 ± 0.78 5.62 ± 0.95 
U87-RFP + SW 87.76 ± 5.73 5.51 ± 2.30 6.73 ± 1.84 
U2OS-RFP 87.39 ± 9.42 5.12 ± 0.64 8.03 ± 1.12 
U2OS-RFP + SW 90.42 ± 5.70 5.61 ± 3.23 4.23 ± 1.20 
MSC and U87-RFP 92.60 ± 4.95 4.80 ± 1.13 2.60 ± 0.57 
MSC and U87-RFP + SW 59.08 ± 0.18 ** 17.27 ± 4.48 ** 23.65 ± 4.22 ** 
MSC and U2OS-RFP 89.85 ± 2.62 4.00 ± 1.41 6.15 ± 1.77 
MSC and U2OS-RFP + SW 58.86 ± 6.72 ** 16.67 ± 3.52 ** 24.47 ± 3.58 ** 
 
Statistical significance between untreated cells or co-cultures and SW-treated cells or co-cultures: * 
p < 0.05, ** p < 0.01. 
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4. Discussion 
 The last decade has witnessed the publication of a large number of studies that describe 
MSC as effective anticancer tools thanks to their selective ability to migrate towards tumor cells 
and deliver cytotoxic drugs, i.e. the “Trojan horse” concept.	Indeed, tumors can produce a large and 
continuous amount of cytokines, chemokines and inflammatory mediators, which are signals 
capable of recruiting respondent cell types, including MSC [36,6,37]. Our recent work on the use of 
MSC as drug delivery vehicles for anti-tumor therapeutic applications, has prompted us to find new 
approaches/techniques that can induce the release of cytotoxic ROS from MSC toward tumor cells 
[3].  
SW have recently gained recognition as a valuable means for the non-invasive and tunable 
induction of specific biological effects [19,20,38]. It is generally accepted that one of the main 
effectors of the non-thermal interactions between ultrasound and biological tissues is acoustic 
cavitation and that it is able to generate short-lived species, such as ROS and free radicals, thanks to 
its high-energy release [39,40]. It has been reported that ultrasound alone, which results in a 
cavitation process, can induce time-dependent apoptotic cell death in in vitro liquid tumors, such as 
human myeloid leukemia and histiocytic lymphoma [41,42]. Indeed, intramembrane cavitation may 
be the mechanism underpinning ultrasound-induced intracellular ROS production [23].  
The purpose of this study is to evaluate whether SW exposed MSC are able to impact on 
cancer cell growth, via MSC/SW mediated ROS generation, in in vitro co-culture models. In 
particular, we investigated two different co-culture systems, MSC + human glioblastoma (U87-
RFP) and MSC + osteosarcoma (U2OS-RFP). The choice of these tumor cell lines is in line with 
the urgent need to find efficient therapeutic systems to treat cancers located in poorly accessible 
areas, such as bones and the brain [43,44].  
Our first experiment investigated the amount of intracellular glutathione (GSH), a potent 
antioxidant that it is generally overexpressed in cancer cells [45], in all the considered cell lines, to 
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find a correlation between GSH content and sensitivity to ROS action. Our data show that a 
substantially higher amount of GSH was present in U2OS-RFP cells. These were followed by U87-
RFP, HDF 106 and finally MSC, indicating that cancer cells, mainly U2OS-RFP, may display a 
better defensive response to oxidative stress. We therefore supposed that cell growth would 
decrease in line with measured GSH levels once cell lines were exposed to the SW treatment. 
Interestingly, significant decreases in cell growth were only observed only in MSC.  
We then evaluated the ability of all the considered cell lines, MSC, HDF 106, U2OS-RFP 
and U87-RFP, to generate ROS upon SW exposure in order to strengthen our hypothesis of a 
particular ROS generating mechanism existing between SW and MSC. Strong and significant ROS 
production was only observed in MSC for up to 60 minutes after SW treatment, highlighting the 
fact that MSC were the most sensitive to SW exposure of all the treated cell lines. Moreover, pre-
incubation of MSC with a ROS scavenger, i.e. NAC, significantly decreased MSC-mediated ROS 
production, as compared to non-pre-treated cells, emphasising the selectivity of the MSC response 
to SW exposure. These combined data point to the peculiar sensitivity that MSC possess to SW 
exposure. 
MSC/SW mediated ROS generation was able to induce a significant decrease in cancer cell 
growth over time and in both cancer cell lines in our co-culture experiments. In particular, the 
reduction in cancer cell growth was very significant (> 40%) in both co-cultures 24 h after SW 
exposure, whereas it was less prominent at 48 and 72 h after treatment. Conversely, the pre-
incubation of MSC with NAC induced a significantly lower decrease in co-culture cell growth, thus 
confirming the ROS-mediated action of the MSC/SW system [46,47]. Our results are in agreement 
with a previously reported study, which describes the generation of ROS during cavitation and how 
the presence of a free radical-scavenger diminishes cells damage [40].  
In order to confirm that the decreased cancer cell growth in SW-treated co-cultures was 
selectively determined by MSC/SW-induced ROS production, we investigated cancer cell growth 
on two separate co-cultures of U87-RFP and U2OS-RFP cells with human dermal fibroblast 
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(HDF106) instead of MSC. Dermal fibroblasts are considered to be mature mesenchymal cells and 
are particularly abundant in the connective areas of each organ and tissue [48]. Moreover, it has 
been reported that MSC and fibroblasts share many characteristics in differentiation, proliferation 
potential, distribution, phenotype and immunoregulation [48,49]. A slight but statistically 
significant decrease in cell growth was only observed in HDF 106 cells treated alone 24 h after SW 
exposure. This may be due to the low level of GSH present, but no decrease in HDF 106 and cancer 
cell growth was observed when HDF106/U87-RFP and U2OS-RFP co-cultures where exposed to 
SW. Once again this data confirm the peculiar biological response that MSC have upon SW 
exposure; producing ROS which are able to kill co-cultured cancer cells. 
Since MSC ROS production after SW exposure seems to be the mechanism involved in 
killing cancer cells in co-culture models, it was decided that we evaluate the degree of lipid 
peroxidation after SW treatment in MSC alone and in co-culture models. Indeed, the lipid 
peroxidation of polyunsaturated fatty acids is one of the major effects induced by oxidative stress 
and one that can dramatically alter cell integrity [50]. We were able to observe a significant increase 
in lipid peroxidation 24 h after SW treatment both in MSC and in MSC/cancer cell co-cultures. The 
significant reduction in cancer cell growth observed in the co-culture models under SW exposure, 
with a MSC/cancer cell ratio of 1:3, is most likely due to the ROS produced by MSC, which leads 
to the significant lipid peroxidation both in MSC and in cancer cells. Our data agree with recent 
work by Leung and co-workers which reported the role of ultrasound in inducing lipid peroxidation 
[51]. 
It has also been reported that ultrasound-induced ROS generation is able to trigger apoptotic 
changes [52]. Therefore we performed a cytofluorimetric analysis of SW-treatment induced cell 
death after 24 h, in order to investigate whether cancer cell growth reduction was due to apoptotic 
and/or necrotic cell death. Our results highlighted very significant increases in both apoptotic and 
necrotic cells in SW-treated MSC/cancer cell co-cultures, as compared to untreated co-cultures, as 
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the cell death of MSC and cancer cells was due to the ROS burst selectively induced in MSC by 
SW exposure. 
Overall, our data show a MSC’s peculiar sensitiveness to SW exposure. It is well known 
how the microenvironment may influence the stem cell behavior, however, only a few studies have 
investigated the role of mechanical stimulations in this contest [53-55]. Our results lead us to take 
the risk of speculating about how an induced-mechanical stress may provoke different cellular 
effects according to cell type dependent features, such as the cytoskeleton. This can lead to 
differences in intracellular cavitation generation under SW exposure, that may not be effective in 
producing reactive oxygen species in some cells, such as cancer cells, but does so in other cells, 
such as MSC [56]. It is worth nothing that our experiments were carried out using SW that are 
characterized by low positive pressure peak (i.e., 31 MPa) that may fit well with the theory, known 
as “bilayer sonophore”, reported by Krasovitski B et al. [23]. This means that the bilayer membrane 
is capable of transforming the oscillating acoustic pressure waves into nanometric and micrometric 
intracellular deformations, under appropriate conditions, which are, in turn, able to induce 
intracellular cavitation without provoking direct mechanical damage to the cell membrane. 
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5. Conclusion 
This study represents the first investigation on the effects of SW treatment on the cell 
growth of human cancer cells co-cultured with mesenchymal stem cells. We demonstrated that 
MSC, under SW exposure, work as “ROS-producers” able to induce significant ROS production 
that in turn triggers a cascade of events in co-cultured cancer cells, including lipid peroxidation that 
leads to cancer cell death. These encouraging preliminary results could pave the way for 
investigations into whether, and how, SW can be used for the stem cell therapy of malignancies. 
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